IMA.US ImageneBio, Inc.

Healthcare Biotechnology USA Stocks
3.47 USD
Close of Nov 15, 2026
3.34 7.89
Market cap
USD 43.2M
P/E
-
P/B
0.34x
ROE
-37.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMA.US undervalued?

Graham number

The Graham number of ImageneBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ImageneBio, Inc. fundamental analysis

No fundamental analysis for ImageneBio, Inc. yet.

ImageneBio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July…

Full company profile